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There is no novelty in stating that conventional 
cancer therapeutics are highly mutagenic, unselective 
and toxic. Hair loss, neutropenia, vomiting, and immune 
suppression are just some of the immediate side effects. 
In addition, genomic damage induced by these agents can 
result in second tumours later in life. Cancer cells differ 
from normal cells in a number of hallmarks that define 
the tumour phenotype [1]. These traits, which involve 
genetic and epigenetic changes in tumour suppressors 
and oncogenes, constitute a double-edged sword for 
cancer cells. They provide a proliferative advantage but, 
importantly from a treatment prospective, also mean an 
increased dependence on certain cellular functions as 
well as an increased vulnerability to particular insults. 
The goal of cancer treatment is to exploit this differential 
sensitivity to selectively kill tumour cells whilst sparing 
normal tissues. Classically, the search for new anticancer 
therapies has focused on the discovery of agents that 
annihilate tumour cells at least as effectively as existing 
chemotherapeutics whilst having weaker or negligible 
effects on healthy tissues. Alternatively, so-called 
cyclotherapy strategies aim at improving the therapeutic 
window by selectively shielding normal cells from 
conventional anticancer drugs [2,3]. The majority of such 
drugs target dividing cells. Hence, if we could transiently 
and selectively pause proliferation in normal tissues, 
subsequent treatment with S- or M-phase poisons should 
eradicate cycling tumour cells only. 
Nutlin-like compounds are well-established non-
genotoxic activators of the p53 pathway [4] currently 
undergoing clinical trials for treating patients with 
cancers retaining wild-type p53. In addition, nutlin-3 has 
been proposed as a potential chemoprotective agent for 
patients bearing tumours with mutant p53. The rationale 
behind this use is that nutlin-3 has been shown to have a 
mild, reversible cytostatic effect on a variety of normal 
cells [5,6]. We believe it is important to highlight these 
observations, as a widely spread view is that activating 
p53 in vivo would trigger severe cytotoxic responses in 
normal tissues. Experimental data supporting this notion 
comes from animal studies where the expression of p53’s 
major negative regulator, mdm2, was suppressed [7]. 
However, such undesired side effects do not occur when 
p53 is activated in a buffered manner using nutlin-3, an 
agent that binds directly to mdm2 [4], partially impairs 
mdm2’s down-regulating activity on p53 [8], and 
stabilises mdm2 [9]. Indeed, nutlin-3 has been shown 
to protect normal cells from mitotic poisons such as 
the aurora kinase inhibitor VX680 [10], taxanes [5,6], 
and polo-like kinase inhibitors [11]. Most interestingly, 
nutlin-3 protects mice from PLK1 (polo-like kinase 
1) inhibitor–induced neutropenia without abating the 
anticancer potency of the mitotic poison [11]. In their 
recent article, Apontes et al., (2011) provide additional 
evidence supporting the potential suitability of nutlin-3 
for cyclotherapy purposes. Indeed, nutlin-3 also protects 
normal  cells  from  nocodazole,  a  compound  that  −like 
the vinca alkaloids used in the clinic− inhibits tubulin 
polymerisation.
The results summarised above suggest that nutlin-3 
could constitute an ideal agent for chemoprotection 
purposes  in  patients  with  p53-deficient  tumours. 
However, the clinical use of this compound has not yet 
been approved. In a recent paper, we tested the possibility 
of using low doses of actinomycin-D, an approved drug 
that at nanomolar concentrations can increase p53 activity 
in a similar manner to nutlin-3 [12]. Yet, there are some 
important differences between the p53 responses to 
nutlin-3 and LDActD that can be understood on the basis 
of their different from mechanisms of action [9]. Like 
nutlin-3, LDActD has a primarily cytostatic effect on p53 
wild-type normal cells and protects them from subsequent 
treatment with VX680 [13]. Unfortunately, LDactD Oncotarget 2011; 2:  274 - 276 275 www.impactjournals.com/oncotarget
pretreament  also  protects  p53-deficient  tumour  cells 
against VX680 to a small extent. Our hope is that LDActD 
might perform better in a p53-based cyclotherapy setting 
when combined with S-phase poisons than with mitotic 
poisons. In this line, nutlin-3 has been shown to prevent 
the mutagenic and cytotoxic effects of gemcitabine and 
cytosine arabinoside in normal cells without diminishing 
the killing effect of these compounds on p53-mutant 
tumour cells [14]. 
In the article featured here [6], aside from nutlin-3, 
Blagosklonny’s group evaluate other clinically-approved 
drugs as chemoprotective agents against the tubulin 
poisons nocodazole and paclitaxel. The two well-known 
drugs chosen for this purpose are rapamycin, a drug with 
striking anti-ageing properties, clinically used to prevent 
transplant organ rejection (in chronic administration 
with traditional immunosuppressants) [15], and the 
anti-diabetic drug metformin. The authors show that 
pretreatment with these drugs succeeds in protecting all 
normal cell types tested against these mitotic poisons, 
whilst having little impact on the vulnerability of a 
cancer cell line with mutant p53. The chemoprotective 
effects might be related to the interesting observations 
that glucose starvation selectively protects primary cells 
against cyclophosphamide in cell culture and fasting 
reduces the side effects of chemotherapy in patients 
[16,17]. Furthermore, evidence suggests that lack of p53 
may sensitise cancer cells to metabolic stresses such as 
nutrient deprivation [18]. The study by Apontes et al. also 
addresses whether combining two chemoprotective agents 
could lead to an even greater increase in the therapeutic 
window of mitotic poisons. In this regard, nutlin-3 plus 
rapamycin and rapamycin plus metformin gave the most 
promising results.
Like  in  the  case  of  the  nutlins,  the  efficacy  of 
metformin and rapamycin is currently being assessed in 
clinical trials for cancer [19,20]. Independently of whether 
these tests are successful, the encouraging data presented 
by Apontes and co-workers suggests that there might be 
other avenues for these compounds in cancer therapy.
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